Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Fluoroquinolones: Is Another FDA Safety Step Needed?

This article was originally published in The Pink Sheet Daily

Executive Summary

Joint advisory committee meeting will discuss post-marketing safety data, including adverse events across organ systems.


Related Content

Fluoroquinolones Get New Safety Labeling, But Not A REMS
FDA Adverse Event Data Clouds Potential Fluoroquinolone Label Changes
Fluoroquinolones Need REMS With Communication Plan, AdCom Says
FDAAA Fading? REMS Use Continues To Decline As Drug Safety Law Matures
Fluoroquinolones To Get “Better” But Not Necessarily Stronger Warning On Nerve Damage
Fluoroquinolone REMS Will Survey Patients, Doctors on Understanding of Risk


Related Companies